Polo-like kinase I (PLK1), a cell cycle regulating kinase, has been shown to have oncogenic
function in several cancers. Although PLK1 inhibitors, such as BI2536, BI6727 (volasertib) …

Cancer is one of the greatest challenges of the modern medicine. Although much effort has
been made in the development of novel cancer therapeutics, it still remains one of the most …

Purpose Polo-like kinase 1 (PLK1) is a protein kinase that is overexpressed in breast cancer
and may represent an attractive target for breast cancer treatment. However, few studies …

Traditionally, bioanalytical laboratories do not report actual concentrations for samples with
results below the LOQ (BLQ) in pharmacokinetic studies. BLQ values are outside the method …

We investigate the personalisation and prediction accuracy of mathematical models for
white blood cell (WBC) count dynamics during consolidation treatment using intermediate or …

Background Volasertib induces mitotic arrest and apoptosis by targeting Polo‐like kinases.
In this phase I dose‐escalation study, the maximum tolerated dose (MTD), pharmacokinetics …

Abstract Polo‐like kinase 1 (Plk1) is an important regulator of the cell cycle and it is
frequently overexpressed in cancer cells. Several small molecule inhibitors have been …

In the oncology field, understanding the relationship between the dose administered and the
exerted effect is particularly important because of the narrow therapeutic index associated …

CPX-351 is a liposome encapsulating cytarabine and daunorubicin for treating Acute
Myeloid Leukemia (AML) patients. To what extent differences in cytidine deaminase (CDA) …

During intensive chemotherapy of acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL), leukopenia and neutropenia are commonly arising adverse events. These …